ROZLYTREK from Roche’s Genentech division is FDA indicated for adult patients with metastatic non-small cell lung cancer whose tumors are ROS1-positive. In addition, it is indicated for adults and children 12 and older with solid tumors. The latter indication requires that the tumors have a neurotrophic tyrosine receptor kinase gene fusion without a known acquired resistance mutation. Other requirements are that the tumors are metastatic or where surgical resection is likely to result in severe morbidity, and that the tumors have progressed following treatment or have no satisfactory alternative therapy.